Dautzenberg F M, Hauger R L
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.
Neuropharmacology. 2001 Mar;40(3):394-407. doi: 10.1016/s0028-3908(00)00167-2.
Pituitary adenylyl cyclase-activating polypeptide (PACAP) receptor type 1 (PAC(1)) signaling and desensitization were investigated in human retinoblastoma Y-79 cells. Concentration-dependent stimulation of cAMP accumulation was observed in Y-79 cells incubated for 30 min with PACAP38, PACAP27, or VIP (10(-12) to 10(-6) M). The following EC(50) values were calculated: PACAP38, 24+/-3 pM; PACAP27, 99+/-8 pM; and VIP, 29+/-3 nM. Homologous desensitization of PAC(1) receptors in Y-79 cells pretreated with 10 nM PACAP38 or PACAP27 for 60 min was characterized by a 30-50% reduction in PACAP-stimulated cAMP accumulation (p<0.0001) and a two- to fivefold rightward shift in EC(50) values (p<0.0001). PAC(1) receptor desensitization was not accompanied by a reduction in PAC(1) mRNA expression. We concluded that the desensitizing effect of PACAP38 was homologous because neither corticotropin-releasing factor- nor (-)-isoproterenol-stimulated cAMP accumulation was altered by PACAP38 preincubation. Pretreating Y-79 cells with the protein kinase A (PKA) inhibitor H89 failed to inhibit homologous PAC(1) receptor desensitization. Similarly, pretreating Y-79 cells with the protein kinase C (PKC) inhibitors staurosporine or bisindolylmaleimide failed to alter homologous PAC(1) receptor desensitization. Although activation of PKA by dibutyryl cAMP or forskolin did not desensitize PAC(1) receptors, direct activation of PKC by PMA heterologously desensitized PAC(1) receptors, reducing cAMP accumulation 34.2+/-2.2% (p<0.001). Using RT-PCR, mRNA levels for G-protein-coupled receptor kinase 3 (GRK3), but not GRK2, were found to increase 2.2- to 4.8-fold in Y-79 cells exposed to PACAP38 for 10 min to 24 h (p<0.001). PAC(1) receptor desensitization decreased 72.5+/-4.3% (p<0.001) in Y-79 cells transfected with a GRK3 antisense cDNA construct that also reduced GRK3 protein expression 48.5+/-7.9% (p<0.0005). These experiments demonstrate that GRK3 plays an important role in the homologous desensitization of retinoblastoma PAC(1) receptors, whereas PKC, but not PKA, contributes to the heterologous desensitization of retinoblastoma PAC(1) receptors.
在人视网膜母细胞瘤Y - 79细胞中研究了垂体腺苷酸环化酶激活多肽(PACAP)1型受体(PAC(1))信号传导和脱敏作用。用PACAP38、PACAP27或血管活性肠肽(VIP,10⁻¹²至10⁻⁶ M)孵育Y - 79细胞30分钟,观察到cAMP积累呈浓度依赖性刺激。计算出以下半数有效浓度(EC(50))值:PACAP38为24±3 pM;PACAP27为99±8 pM;VIP为29±3 nM。用10 nM PACAP38或PACAP27预处理Y - 79细胞60分钟后,PAC(1)受体的同源脱敏表现为PACAP刺激的cAMP积累减少30 - 50%(p<0.0001),EC(50)值向右移动2至5倍(p<0.0001)。PAC(1)受体脱敏并未伴随PAC(1) mRNA表达的降低。我们得出结论,PACAP38的脱敏作用是同源性的,因为促肾上腺皮质激素释放因子或( - ) - 异丙肾上腺素刺激的cAMP积累并未因PACAP38预孵育而改变。用蛋白激酶A(PKA)抑制剂H89预处理Y - 79细胞未能抑制同源性PAC(1)受体脱敏。同样,用蛋白激酶C(PKC)抑制剂星形孢菌素或双吲哚基马来酰胺预处理Y - 79细胞也未能改变同源性PAC(1)受体脱敏。虽然二丁酰cAMP或福斯可林激活PKA并未使PAC(1)受体脱敏,但佛波酯直接激活PKC可使PAC(1)受体异源脱敏,使cAMP积累减少34.2±2.2%(p<0.001)。使用逆转录 - 聚合酶链反应(RT - PCR)发现,在暴露于PACAP38 10分钟至24小时的Y - 79细胞中,G蛋白偶联受体激酶3(GRK3)的mRNA水平增加了2.2至4.8倍(p<0.001),而GRK2的mRNA水平未增加。在用GRK3反义cDNA构建体转染的Y - 79细胞中,GRK3蛋白表达也降低了48.5±7.9%(p<0.0005),PAC(1)受体脱敏降低了72.5±4.3%(p<0.001)。这些实验表明,GRK3在视网膜母细胞瘤PAC(1)受体的同源脱敏中起重要作用,而PKC(而非PKA)有助于视网膜母细胞瘤PAC(1)受体的异源脱敏。